Cephalon News

Utility AES sees spate of call selling : The electric utility has been dead money for the last three months, and now one investor may be throwing in the towel.

A flex building in West Chester traded for $12 million, or more than $90 a square foot, in what is a strong showing for that type of building.

Main Category: Lymphoma / Leukemia / Myeloma Also Included In: Pharma Industry / Biotech Industry Cephalon, Inc.

" November 5, 2009 - " Cephalon, Inc. today announced the journal Cancer has published a pivotal study demonstrating that TREANDAA for Injection induced durable responses in patients with indolent B-cell non-Hodgkin's lymphoma whose disease had progressed during or within six months of treatment with rituximab.

Alkermes Inc. filed Quarterly Report for the period ended 2009-09-30. Alkermes Inc.

Cephalon specializes in bio-pharmaceuticals that target central nervous system disorders, pain treatments, and oncology .

Cephalon, Inc. today announced that the November issue of Mayo Clinic Proceedings has published data from a pivotal Phase III trial demonstrating that NUVIGIL Tablets [C-IV] significantly improved wakefulness throughout the shift in patients with excessive sleepiness associated with shift work disorder .

If you think to invest in healthcare industry amid the government controlled reform, you may want to look at Edward Owens a TM Vanguard Healthcare Fund portfolio.

Covidien PLC said Friday it expects to start selling a generic version of the painkiller Actiq in early 2010.

Cheap stocks can get cheaper . They often do. Unfortunately, "cheap" is a relative term.

Cephalon paying $30 million upfront in buyout option deal for BioAssets Development.

Cephalon Inc. on Tuesday said third-quarter earnings fell from a year ago, when the biotech firm recorded a $66.1 million tax benefit.

Cephalon Inc. signed an option agreement Monday to acquire BioAssets Development Corp.

Cephalon, Inc. and BioAssets Development Corporation , a privately held biopharmaceutical company, today announced that the companies have signed an agreement that will provide Cephalon with an option to acquire BDC.

Stocks were trading mixed early Thursday, as investors digested another hefty dose of earnings news.

Cephalon, Inc. recently received a Paragraph IV Certification Notice Letter regarding an Abbreviated New Drug Application , which has been filed by Teva Pharmaceuticals with the U.S. Food and Drug Administration .

Although Cephalon did not announce significant news Thursday, at least one investor is taking a bullish stance on the drug manufacturer and boosting call volume days ahead of the company's earnings.

Israeli stocks were down on Thursday, as strength in Israel Chemicals and its parent were more than offset by broad weakness among the blue chips and the tech sector.

In Q3 2009, life science and biotech stocks kept pace with market sectors that offer comparable risk and performance such as small-cap growth, science and technology, and midcap growth.

David Sauter, the Republican candidate for supervisor in the town of Canandaigua, has dropped out of the race, citing business obligations.